Connect with us

European Alliance for Personalised Medicine

EAPM: The blood is the life – key work on blood cancers needed with respect to the upcoming European Beating Cancer Plan

SHARE:

Published

on

Good afternoon, and welcome to the second update of the week from the European Alliance for Personalised Medicine (EAPM). With the upcoming Europe’s Beating Cancer Plan (scheduled for its formal launch on 3 or 4 February, depending on whether DG SANTE or the Commission are correct in their predictions), health discussions will inevitably turn to how the noble aim of the campaign is likely to be achieved, and EAPM Executive Director Dr. Denis Horgan turns his particular attention to cancers of the blood. 

Beating blood cancers

Over the years, the EAPM has worked extensively with its members, particularly the European Haematology Association as well as the relevant patient organizations focus on the need for continual work towards reducing and combating the prevalence of blood cancer Such cancers (hematological malignancies (HMs) to give them their correct moniker) are frequently overlooked and, following recent discussions, it is understood that that may not be as prominently covered as they should be.  

Advertisement

HMs are a heterogeneous group of diseases of diverse incidence, and prognosis, and comparison of HM incidence across regions and over time is complicated by the existence of different disease classification systems. Obviously, incidence is one of the biggest and best measures of burden in a population, serving as a vital guide to the allocation of resources.

Statistics suggest that health-care costs for each patient with blood cancer reach twice the figure compared to average cancer costs. The total cost of blood disorders to the European economy was in the region of €23 billion in 2012 and is only increasing.

Blood cancers are in the top ten of the most common forms of cancer and are responsible for approximately 100,000 deaths in Europe every year. Some of the most critical cancers are Multiple Myeloma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin’s Lymphoma, Myelodysplastic Syndrome, and Pediatric Hematological Malignancies.

These cancers present a serious medical and financial challenge and account for abround 40% of cancer cases in children and one third of overall cancer deaths. However, it has been suggested that the upcoming Europe’s Beating Cancer Plan is not as yet paying as much attention to blood cancers as it should.

EAPM and its key stakeholders believe that this is a gap that should be urgently addressed in the upcoming EU Beating Cancer Plan, as blood disorders are not only a burden for patients, but also for society as a whole, with around 80 million people having either malignant or non-malignant haematological disorders. We need to urgently step up how Europe tackles this and the European Beating Cancer Plan can support this common EU effort.

Transforming lung cancer care

Europe's approach to lung cancer (LC) needs a transformation in national care pathways as well as local and country policies. LC care receives high priority within only a few national health strategies. But it is largely up to the member states – incentivized by the European Union – to recognize that reorganization and reallocation of health-care resources are justified by the current massive costs to individuals and to society of the growing incidence of this type of cancer.

Improvements in outcomes are within reach but depend heavily on: 

  • A more uniform approach to national risk-based screening programmes to identify patients early and decrease the rate of patients diagnosed in advanced/metastatic stages;

  • early access to comprehensive genomic profiling;

  • the identification of most appropriate treatment pathways based on the patient’s tumour genetics through multi-disciplinary molecular tumour boards;

  • fast and broad access to most beneficial treatment options;

  • adequate monitoring of patients including patient reported outcomes that will allow for targeted interventions, and;

  • the integration of patient data to gain further insights for research, validity of clinical treatment pathways and cost-efficiency of comprehensive diagnostics and targeted medicines.

These are key issues that should be taken into account as highlighted by the multistakeholder engagement that EAPM has undertaken. 

Stop finger-pointing over vaccination and get to work, says Commission

We are racing against time, not against each other,” Health Commissioner Stella Kyriakides said on Tuesday (19 January). “On the contrary, it is a race that we in the EU are running together, as a team and in unity. As a team, it is important to set clear and ambitious targets.”

And the Commission has set vaccination goals for March and the summer, and backed a bare-bones vaccine certificate. Vice President Margaritis Schinas left the door open to using them later for travel.

Leaders consider travel bans and faster vaccine rollout 

Ursula von der Leyen and European Council President Charles Michel concluded a virtual meeting of EU leaders on Thursday (21 January). European leaders, struggling with a slow vaccination effort and fearful that highly contagious coronavirus variants could rapidly overwhelm their medical systems, moved to begin reimposing border restrictions and to speed the distribution of vaccines — even those not yet approved for use.

We are increasingly concerned about different variants of the virus,” von der Leyen told reporters after a virtual summit of European Union leaders, saying that although the bloc intends to keep borders open for trade, it may restrict nonessential travel. The leaders held back from endorsing a specific plan for borders.

But Germany — which as the richest and most populous EU member often drives its discussions — proposed strict, temporary bans on travel to the EU from countries where mutated forms of the coronavirus are already prevalent, including Britain. The proposal would restrict EU citizens from returning to their home countries if they are currently in an affected country, and would therefore be more stringent than previous border measures. 

The coronavirus situation is deteriorating so badly in some member states that EU leaders have agreed to create a new “dark red” zone indicating the virus is spreading at a “very high level”, Commission President Ursula von der Leyen announced Thursday night (21 January). People traveling from a dark red to another zone could be required to get a test before leaving and might need to quarantine upon arrival. 

France to impose COVID testing on EU travellers

France’s President Emmanuel Macron has announced new coronavirus rules for travellers from the EU, with the country requiring European visitors as well as those from outside the bloc to have a negative Covid-19 test performed less than three days before they enter the country. 

The new restrictive measures, to come into effect from Sunday morning (24 January), were announced by the Elysée Palace late on Thursday and follow an EU summit by videoconference at which leaders discussed measures to control the pandemic with continuing vaccination programmes and controls on free movement. Until now, Macron had sought to maintain freedom of movement within Europe, but pressure on hospitals and the spread of new, more infectious variants of the virus have convinced him of the need to extend testing to almost all those crossing national borders. 

Hungary first in EU to approve Russian vaccine

Hungary has become the first country in the European Union to give preliminary approval to the Russian coronavirus vaccine, Sputnik V. On Thursday, Prime Minister Viktor Orban's chief of staff confirmed both the Russian jab and the Oxford-AstraZeneca vaccine had been given the green light by the health authorities. Foreign Minister Peter Szijjarto is travelling to Moscow for further talks, where he is expected to discuss a shipment and distribution deal.  

And that is all from EAPM for this week – have an excellent, safe weekend, stay well, and see you next week.

European Alliance for Personalised Medicine

EAPM: COVID cases fall but Europe prepares for fourth wave

Published

on

Good morning, health colleagues, and welcome to the second European Alliance for Personalised Medicine (EAPM) update of the week, before the August break, but EAPM will be with you throughout summer, writes EAPM Executive Director Denis Horgan.

Deadline for orphan and pediatric consultation 

Today (30 July) is the deadline for the public consultation on the revision of EU rules on medicines for children and rare diseases — and the process has been ongoing, in November 2020, the Commission published an inception impact assessment evaluating proposals to change EU regulations for medicines for rare diseases and for children. The Commission concluded that the orphan regulation has had a positive impact by adding 210,000-440,000 quality-adjusted life years for patients in the EU despite increasing costs by €23 billion from 2000-2017. Nearly three quarters (73%) of orphan medicines had annual sales of less than €50 million in the European Economic Area, while only 14% had annual sales over €100 million. The report found that orphan medicines on average received an additional 3.4 years of market exclusivity, which equates to about 30% of sales revenue for those products. While some sponsors may have been “overcompensated,” the Commission says that the additional market exclusivity “has helped to increase profitability, without giving the sponsor an unbalanced compensation” in most cases. The evaluation also looks at whether the current threshold of affecting fewer than 5 in 10,000 patients in the EU “is the right tool” for defining rare diseases.

Advertisement

EIF looks to decentralized software architecture

Fabric Ventures, a venture manager that backs ‘open economy’ founders across the globe, has today (30 July) announced Europe’s biggest fund of its type, valued at $130 million, which includes $30 million from the European Investment Fund (EIF). Fabric Ventures’ 2021 fund is the very first EIF-backed fund specifically mandated to invest in digital assets. It will back traditional equity as well as the software tokens and other digital assets native to these new, inclusive and collaborative networks and applications. These are all underpinned by the recent invention of digital scarcity and hence ownership. The founders of the open economy frequently have the explicit objective of delivering solutions to many of humanity’s most fundamental challenges, particularly health concerns.

Third vaccine doses set to begin

European countries have yet to start rolling out booster shots, although several countries have said they plan to — including Hungary, which is set to start on Sunday (1 August). Last week, Israel published data indicating that the effectiveness of the Pfizer/BioNTech vaccine could drop to 39%.The data has added further fuel to Israel’s justification to give a third dose.  Hungary would become the first EU country to offer a booster if it also goes ahead with plans to start offering the shot on Sunday. Alongside BioNTech/Pfizer, Oxford/AstraZeneca, Moderna and J&J vaccines, Hungary has also used Sputnik V vaccines and jabs from China’s Sinopharm. It’s unclear which vaccine would be used as a booster shot. 

COVID-19 hospitalizations and deaths are increasing due to Delta

The surge in COVID-19 cases fuelled by the Delta variant and vaccine hesitancy has now led to increasing rates of hospitalizations and deaths. Data from Johns Hopkins University shows that the average number of new COVID-19 cases each day in the past week was 32,278. That's a 66% jump from the average daily rate the previous week, and 145% higher than the rate from two weeks ago. There's a common theme among those behind the worsening COVID-19 numbers, said Dr. Rochelle Walensky, director of the US Centers for Disease Control and Prevention. "This is becoming a pandemic of the unvaccinated," Walensky said at a COVID-19 briefing.

Austria to set out guidelines on ‘long’ COVID

Austria is setting out new guidelines for long COVID, with doctors set to receive advice on identifying and treating patients. The health ministry said that current estimates indicate that 10-20% of all people infected with coronavirus could have long-term consequences. The announcement comes as countries look to provide more support for patients who are still living with side effects long after having recovered from the virus.

Germany's divided over pandemic strategy

German Health Minister Jens Spahn rebutted experts at the Robert Koch Institute (RKI), who have been arguing that the infection rate should remain the leading indicator for pandemic management. Spahn argued that increasing levels of immunization mean that the rate of infections is less meaningful than it used to be. What’s needed are “additional data points to assess the situation” Spahn said, adding as an example the “number of newly admitted [COVID-19] patients in hospitals”. That rate has recently been rising again, but like elsewhere in Europe, hospitalizations are well below the peaks from the pandemic. That led Spahn to recently proclaim that a higher cut-off is now acceptable because infections lead to far fewer hospitalizations than they used to, and therefore fresh lockdown measures are not needed. Spahn’s position also aligns him with some of Germany’s state premiers, who disagree with Wieler and want to keep the economy as open as possible.

EU faces difficulties in repaying recovery fund's joint debt

The European Commission will shortly start transferring billions in grants and loans to EU member countries under its €750 billion pandemic recovery fund — but its plan to repay the borrowings through new levies at the EU level is unraveling.

The recovery fund — known as Next Generation EU — came together last summer after EU leaders reached an unprecedented agreement to issue hundreds of billions in joint debt to help the bloc’s economy get through the COVID-19 crisis. But the details of reimbursement, which will stretch over three decades, were left to the Commission to propose.  

Should all EU attempts to generate the revenue fail to deliver the needed sum of €15 billion a year, countries will have to cough up increased amounts for the EU’s budget starting from the next budget cycle in 2028 — a highly unpalatable option for countries in Northern Europe that are net contributors to the bloc’s budget. Another option is cutting programs, which in turn would upset net beneficiaries of EU funds like Central and Eastern European countries.

Taxing the behemoths

Mammoth digital services companies like Facebook, Google and Amazon are practised and skilled in the art of manipulating global tax laws - entirely legally, it should be said - to pay as little tax as possible.

There is a growing consensus that these humungous entities, whose borderless products can earn hundreds of millions in revenue while maintaining a skeleton staff on shore, are skirting their obligations.

Numerous ideas have been floated to force these corporations to pay more: Australia and the UK introduced 'Google taxes', aimed at forcing companies that channel their profits through offshore administrations to pay a higher tax rate.

Earlier in July, the G20 and OECD unveiled a new idea - to introduce a global minimum tax rate of 15%, thus enabling millions to be raised for essential services such as health.

Fourth coronavirus wave in Europe

Europe is dealing with the highly contagious Delta variant, first identified in India, which is threatening to prolong the pandemic and derail economic recovery. Authorities are stepping up efforts to facilitate mass vaccination and are ramping up outreach to those who have not made appointments. After a year-and-a-half of relentless fighting against the disease, coronavirus is showing tenacity while a fourth wave of contamination has started and is expected to make European ICUs very busy again in the fall.

Good news to finish: Cases fall dramatically in UK

Cases are falling dramatically in the UK — and epidemiologist Neil Ferguson told BBC Radio 4 that vaccines had changed the threat of COVID-19. “The effect of vaccines is hugely reducing the risk of hospitalizations and death, and I’m positive that by late September or October-time we will be looking back at most of the pandemic,” he said.

That is all from EAPM for now – during August, EAPM will be doing one update per week, so make sure you stay safe and well and have an excellent weekend.

Continue Reading

European Alliance for Personalised Medicine

EAPM: Successful IVDR meeting points the way to future collaborations

Published

on

Good afternoon, health colleagues, and welcome to the second European Alliance for Personalised Medicine (EAPM) update of the week, in which we discuss the successful In Vitro Diagnostic Regulation (IVDR) meeting conducted by EAPM yesterday (22 July), and other pressing health issues, writes EAPM Executive Director Dr. Denis Horgan. 

IVDR issues raised

Yesterday, EAPM was pleased to have conducted a successful meeting on In Vitro Diagnostic Regulation (IVDR), with more than 73 representatives from 15 countries participating as well as the European Medicines Agency (EMA) and member states’ representatives. 

Advertisement

The IVDR will come into force on 26 May 2022. There are a number of areas in which there is a lack of awareness or clear guidance to support implementation at member state level. The main areas of concern relate to two issues, namely the limited capacity within Notified Bodies to grant CE marking in a timely manner, with a bottleneck occurring in the approval of some IVDs which are likely to be used for patient selection for use with precision medicines. The Commission’s Medical Device Coordination Group (MDCG) Task Force is reviewing this.

In addition, a significant proportion of predictive testing in Europe to support access to oncology precision medicines is delivered through the use of laboratory developed tests (LDTs), and there will be a new legal requirement for labs to use commercially approved tests (CE-IVD) in place of their current LDTs. If there is no CE-IVD commercial test available, public laboratories may be able to use an LDT, subject to certain provisions in the IVDR. The lab will be required to meet all the relevant requirements for safety and performance, whilst carrying out the manufacture under an appropriate quality management system.

Although health institutions are broadly aware of the IVDR, further guidance for laboratories on compliance with its key provisions would be welcomed, particularly on the exemptions to the Regulation granted under Article 5. An MDCG Task Force has very recently been established to develop such guidance, although there is little time left for laboratories to prepare for the regulation. 

Another key issue was whether member states are expecting cost impacts as a result of the IVDR (incurred through either the switch from LDTs to CE-IVDs or the need to improve their laboratory’s quality and performance processes), and whether they have engaged with their national health authority or other relevant stakeholders on this issue. 

Finally, a key outcome of the meeting was the issue of how the regulation can facilitate some of the solutions that were proposed by member states’ representatives, and a meeting will be organized with the Commission and member states at a later date. 

On to other EU health news...

Making Europe fit for the digital age

The EU continues to lag behind China and the US when it comes to investments into key technologies such as artificial intelligence and quantum computing, the European Commission President Ursula von der Leyen has warned. “Europe is still punching well below its weight. I believe this is because of two main reasons. The first one obvious, a lack of investment,” she said. 

While European companies invest massively in research and development in sectors such as automotive or pharma, “our investment in other fields still lags behind the US and China” she added. “Artificial intelligence and quantum computing are two good examples, and due to this, far too many European startups in the tech world have had to leave the continent in order to scale up.”

Bulgaria creates patients rights’ body

Bulgaria’s council of ministers has given the go-ahead to the creation of a new directorate for patients rights under the health ministry. The new body will aid the health ministry in ensuring that patients rights are protected and work on creating programs and guidelines to improve patient protections. Generally, in Bulgaria the rights envisaged in the European legislative framework have been regulated. 

A person’s rights, including in a situation of illness (when a person is in the position of a “ patient” ) are part of the human rights regulated by the UN convention ratified in Bulgaria in 1992. 

The citizens of the Republic of Bulgaria are entitled to accessible health care and health insurance (Art. 52 ofthe Constitution, Art. 33, 35 of the Health Insurance Act (HIA)), healthy environ-ment and conditions of work, guaranteed food quality and protection against abuse of their personality. Each patient is entitled to obtain the best healthcare in conformity with the legislation. 

Cyber concerns on health 

Plans to set up an EU rapid-response cyber unit that could quickly respond to attacks like the recent ransomware hack of Ireland’s Health Service Executive (HSE) have been unveiled. Across Europe, cyberattacks rose 75% last year, with 756 such incidents logged, including an increasing number of attacks on health-care systems, representing a growing risk to society with critical infrastructure at stake, according to the European Commission. “We have a lot of cyber enemies around us,” 

European Commissioner Thierry Breton said. “Ireland’s public healthcare system suffered a pretty strong ransomware attack. I believe it affected a system with more than 80,000 computers, so that was something which was pretty, pretty strong. It could have been a very important plus, if we could have sent dedicated experts very quickly to react even faster, because we know that, of course, the longer you wait the worse it is.” 

The HSE expects it will take as long as six months to recover from the attack, with many hospital and patient data systems still affected. The cyberattack was part of a growing trend of attacks on critical systems, including on the Colonial Pipeline in the US.

Spain offers to test-run the EU's AI regulation

Spain has pitched itself to the European Commission as a laboratory to test the Artificial Intelligence Act - with more 117 AI ethics initiatives springing up around the world, initiatives to regulate artificial intelligence (AI) have sprung up around the world, spearheaded by the likes of Spain, OECD and UNESCO. It‘s time to harmonize and consolidate, a conference on AI ethics held under the auspices of Slovenia’s presidency of the EU Council heard this week. “We are clearly at a developmental point where you’ve got a lot of actors right now contributing to this movement from principles to practice, and we simply need to work together in a multistakeholder way to harmonize these approaches,” said David Leslie, of the Council of Europe’s Ad hoc Committee on Artificial Intelligence (CAHAI). 

WTO and WHO demand more vaccines

The World Trade Organization (WTO) and the World Health Organization (WHO) The World Trade Organization (WTO) have mapped critical inputs for the production of COVID-19 vaccines, in a bid to clarify complex supply chains for sourcing raw materials and components. The organizations this week published an indicative list of 83 inputs, most of which cover the manufacturing of coronavirus jabs, but also those relevant to storage, distribution and administration. It covers the vaccines produced by AstraZeneca, Janssen, Moderna and Pfizer-BioNTech, including product details and their likely HS codes when exported. The list was jointly produced with the Asian Development Bank, the OECD and the World Customs Organization, as well as representatives from the pharmaceutical industry, academia and logistics. It is subject to further modification and improvement depending on expert advice, the WTO says. The exercise was carried out amid concerns over the rate of vaccine production.

MEPs call for mutual recognition of intensivists

While Europe is getting ready to spend a second summer under the shadow of COVID-19, European decision-makers are pushing forward an ambitious agenda and preparing to deliver a more resilient and sustainable European Health Union. To make the best use of the hard-learned lessons from the pandemic, policymakers are now joining the call of the heroes of this unprecedented health crisis: the health-care workers in Intensive Care Units (intensivists) who came under enormous pressure and outdid themselves constantly to save lives. Pandemics don’t stop at our borders and Members of the European Parliament (MEPs) acknowledge the need for European solutions to a European problem. In a letter addressed to European Commission President Ursula von der Leyen, MEPs urge for intensive care medicine to be recognized as a main pillar of the new European Health Union. According to the MEPs, there is a lack of mutual recognition for intensive care medicine training among many EU countries, which prevents a fast and efficient European response in times of pandemics and other cross-border health threats.

Good news to end: EU countries double vaccine-sharing promise to 200M doses

EU countries have committed to sharing 200 million doses of coronavirus vaccines to low- and middle-income countries by the end of 2021, doubling a previous commitment.

The Commission has also pointed today to its other efforts to increase access to vaccines in Africa in particular, however the EU remains firmly opposed to a waiver of intellectual property rights for coronavirus vaccines.

That is all from EAPM for now – make sure you stay safe and well and have an excellent weekend, see you next week.

Continue Reading

European Alliance for Personalised Medicine

EAPM: Truly active summer ahead for EU health policy

Published

on

Good afternoon, health colleagues, and welcome to the first European Alliance for Personalised Medicine (EAPM) update of the week, in which we discuss the range of items ahead for the summer months as far as EU health policy is concerned, so it’s a busy time ahead for EAPM, writes EAPM Executive Director Dr. Denis Horgan. 

In-vitro diagnostic expert panel

And it is a busy week for EAPM, with an in-vitro diagnostic expert panel on Thursday (22 July). This deals with legislation that is due to come into force next year on 26 May, 2022 - the question will be how will this legislation have an impact on bringing innovation into health-care systems and being able to diagnose patients earlier? 

Advertisement

At present a significant proportion of predictive testing in Europe to support access to oncology precision medicines is delivered through the use of laboratory developed tests (LDTs), with the following implications under the IVDR, and there will be a new legal requirement for labs to use commercially approved tests (CE-IVD) in place of their current LDTs. If there is no CE-IVD commercial test available, public laboratories may be able to use an LDT, subject to certain provisions in the IVDR. 

The lab will be required to meet all the relevant requirements for safety and performance, whilst carrying out the manufacture under an appropriate quality management system. As a consequence, many laboratories may face additional procurement costs for commercially approved tests and/or the need to improve their safety and performance requirements for any LDT offerings.

All these issues will be discussed in the expert panel this Thursday through various case studies. A policy paper will be the outcome of this meeting so more on this in the months ahead. 

EU Health Union 

As discussed in the previous updates, the European Health Union package includes proposals to strengthen the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC), and a regulation on cross-border health threats. 

Slovenia, who holds the EU Presidency now and its predecessors at the helm of the EU, Portugal and Germany, are working to finalize negotiations on three draft regulations that form the basis of the EU Health Union, Slovenian Health Minister Janez Poklukar has said. 

The desire is to co-ordinate the regulations in trialogue with other EU institutions as soon as possible, the minister added in a statement. The comments came after a high-level conference on implementing innovative solutions for resilient health systems that also featured the health ministers of Portugal and Germany, Marta Temida and Jens Spahn. Spahn said the shared objective of all three countries was to establish a trialogue with the European Parliament and the Commission. 

“We want actual results in practice,” Spahn added. Temida said it was essential that the work done by the German and Portuguese presidencies continues to produce good results and that the transition was smooth. 

She said adoption of the legislative package would mark “a significant milestone in Europe’s preparedness for extraordinary health events”. The Health Union package includes proposals to strengthen the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC), and a regulation on cross-border health threats.

Research and innovation 

The Commission has adopted its proposal for a Council Recommendation on ‘A Pact for Research and Innovation in Europe' to support the implementation of national European Research Area (ERA) policies.

This is an issue that the EAPM has followed closely. 

The Pact proposal defines shared priority areas for joint action in support of the ERA, sets out the ambition for investments and reforms, and constitutes the basis for a simplified policy coordination and monitoring process at EU and member states' level through an ERA platform where member states can share their reform and investment approaches to enhance exchanges of best practices. Importantly, to ensure an impactful ERA, the Pact foresees the engagement with research and innovation stakeholders. 

A Europe fit for the Digital Age Executive Vice President Margrethe Vestager said: “The pandemic has shown us the importance of uniting research and innovation efforts that swiftly bring results to the market. It has shown us the importance of investment in jointly agreed strategic priorities between Member States and the EU. 

"The Pact for Research and Innovation we propose today, will facilitate better collaboration and join our efforts to tackle research and innovation objectives that matter the most for Europe. And it will allow all of us to learn from each other.” 

New rules on open data and reuse of public sector information start to apply 

17 July marked the deadline for member states to transpose the revised Directive on open data and reuse of public sector information into national law. The updated rules will stimulate the development of innovative solutions such as mobility apps, increase transparency by opening the access to publicly funded research data, and support new technologies, including artificial intelligence. 

A Europe Fit for the Digital Age Executive Vice President Margrethe Vestager said: “With our Data Strategy, we are defining a European approach to unlock the benefits of data. The new directive is key to make the vast and valuable pool of resources produced by public bodies available for reuse. Resources that have already been paid by the taxpayer. So the society and the economy can benefit from more transparency in the public sector and innovative products.” 

Internal Market Commissioner Thierry Breton said: “These rules on open data and reuse of public sector information will enable us to overcome the barriers that prevent the full re-use of public sector data, in particular for SMEs. The total direct economic value of these data is expected to quadruple from €52 billion in 2018 for the EU member states and the UK to €194bn in 2030. Increased business opportunities will benefit all EU citizens thanks to new services.” 

Commission to make HERA proposal on 14 September

The European Commission will present its European Health Emergency Preparedness and Response Authority (HERA) package on 14 September. The COVID-19 pandemic demonstrated the need for co-ordinated EU level action to respond to health emergencies. It revealed gaps in foresight, including demand/supply dimensions, preparedness and response tools. 

A European HERA is a central element for strengthening the European Health Union with better EU preparedness and response to serious cross-border health threats, by enabling rapid availability, access and distribution of needed countermeasures. Last year, the Commission proposed changing the mandates for both the EU’s infectious disease agency and medicines agency, and made a proposal for a regulation on serious cross-border health threats.

Some good news to end: COVID-19 antibodies persist 'at least nine months after infection', study finds 

Antibodies in COVID-19 patients remain high even nine months after infection, according to a landmark study which tested almost the entirety of a small Italian town. The study, published in the journal Nature Communications, focused on the town of Vo which became the centre of the country's coronavirus pandemic in February 2020 when it recorded Italy's first death. 

Now, researchers from the University of Padua and Imperial College London have tested more than 85% of the town's 3,000 residents for antibodies against COVID-19. 

The researchers found that 98.8% of people who had been infected in the first wave of the pandemic were still showing detectable levels of antibodies nine months later, regardless of whether their infection had been symptomatic or not. Residents' antibody levels were tracked using three different "assays", or tests that detected separate kinds of antibodies which respond to different parts of the virus.

That is all from EAPM for now  - make sure you stay safe and well and have an excellent week, see you on Friday.

Continue Reading
Advertisement
Advertisement
Advertisement

Trending